Hemant Surgical Industries Ltd (HSIL) Fair Value & Analysis
Consumer Cyclical · IN · Market cap ₹5.3B
Risks
Fair value as of: Aug 22, 2026
From 17 valuation models · updated 3 days ago
A solid business, but trading 86% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹253.89). The favourable scenario is already priced in.
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹123.11 to ₹253.89) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
60‑month range ₹91.95 – ₹1,283 · fair‑value band ₹123.11 – ₹253.89 · the ₹378.35 price screens above the ₹203.11 fair value. Dashed = 300-day average. As of Aug 22, 2026.
Analysis
Hemant Surgical Industries Ltd (HSIL) currently trades at ₹378.35, while our model-based Fair Value estimate is ₹203.11, implying the stock looks roughly 46.3% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Hemant Surgical Industries Ltd generated revenue of ₹2.3B at a net margin of 7.9%. It earns a return on equity of 18.1%. Net debt stands at ₹58.1M. The stock trades on a trailing P/E of 25.3. Fundamentals as of Aug 22, 2026
Our scenario range runs from ₹123.11 (bear case) to ₹253.89 (bull case); at ₹378.35, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high and 306% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at 23% fair-value upside, at -46%, HSIL screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Growth Earnings (₹581.36) versus Asset-Based (₹63.44). Highest evidence: Residual Income (76).
Notify me when HSIL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 64
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hemant Surgical Industries Ltd reported revenue of ₹2.3B in FY2025 versus ₹180M in FY2021, a compound +89.4%/yr. Reported net income was ₹182M in FY2025, compounding +102.4%/yr from FY2021.
HSIL screens 46% overvalued. Compare with JFC →
Peer Group
Consumer Discretionary · 3767 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Hotels & Entertainment Services” was too small, so the broader sector is used.)
Valuation Multiples vs Consumer Discretionary median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Hotels & Entertainment Services stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JFC JFC | 145.80 PHP | 213.60 PHP | +47% |
| BLOOM BLOOM | 2.38 PHP | 2.13 PHP | -11% |
| 505533 505533 | ₹582.55 | ₹74.51 | -87% |
| Ananti Inc 025980 | 3,910 KRW | 2,758 KRW | -29% |
| PIZZA PIZZA | 6.00 PHP | 11.23 PHP | +87% |
| PT Hotel Mandarine Regency Tbk HOME | 50.00 IDR | 85.45 IDR | +71% |
| Modetour Network Inc 080160 | 8,990 KRW | 11,028 KRW | +23% |
| MAXS MAXS | 2.12 PHP | 2.36 PHP | +11% |
| PT Marga Abhinaya Abadi Tbk MABA | 50.00 IDR | 12.14 IDR | -76% |
| Very Good Tour Co 094850 | 4,155 KRW | 12,684 KRW | +205% |
Compare Hemant Surgical Industries Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Hemant Surgical Industries Ltd (HSIL) overvalued or undervalued?
What is the fair value of HSIL?
What is the quality score of HSIL?
What is the revenue of Hemant Surgical Industries Ltd (HSIL)?
What is the net profit margin of HSIL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hemant Surgical Industries Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.